Q4 2019 Earnings Call
Please standby.
Good day, everyone and welcome to the quarter Q4 earnings Conference call Today's conference is being recorded.
At this time I would like to turn the conference over to make in Britain. Please go ahead ma'am.
Good morning, and welcome to the fourth quarter full year 2019 earnings conference call for courts have I retire.
Hopefully be able to investors and media by webcast.
Yeah prepared presentation slides to supplement our comments during this call. These slides are posted on the Investor Relations section of the for Teva website and through the linked to our webcast.
Moving on the call today, our Jim Collins, Chief Executive Officer, Hamblin, Executive Vice President and Chief Commercial Officer, Roger on the Giardia Executive Vice President of business platform, and Greg Friedman Executive Vice President and Chief Financial Officer.
During this call will make forward looking statements regarding our expectations for the future slides two and three of our earnings release contain our forward looking statement disclaimer.
Statements that address expectations or projections about the future are forward looking statements.
These statements reflect our current expectations, but are not guarantees of future performance and are subject to risks and uncertainties regarding assumptions.
I think the filings provide discussion of some of the factors that could cause material differences and our actual results.
We are providing information on a pro forma basis prepared in conformity with regulation effect to provide the most meaningful comparison, we provide a pro forma based discussion in our earnings release and slide.
Unless otherwise specified all historical financial measures presented today exclude significant items, which can be found in the schedule that accompany our earnings release.
We will also refer to non-GAAP measure a reconciliation to the most directly comparable GAAP financial measure where available and other associated disclosures are contained in our earnings release and on our website.
It's now my pleasure to turn the call over to Jeff.
Thank you Meghan and thank you and welcome to the participants joining the call earlier today, we reported fourth quarter and full year results for 2019.
Our key operational performance indicators for the full year captured on chart for.
Net sales on a reported basis decreased 3% versus the prior year, primarily due to currency.
On an organic basis net sales were flat as weather related declines in North America were offset by above market organic growth in other regions.
In North America reported net sales were up 1% inorganic sales were up 7% demonstrating the strength of our pipeline brands and multichannel distribution strategy.
Operating EBITDA declined 4% compared to prior year, largely driven by currency and weather related price and volume declines in North America.
Continued realization of cost synergies disciplined spending actions increased sales from new products and gains on divestitures were a benefit.
Operating EBITDA margin declined 10 basis points for the full year for the company.
Crop protection, new product sales and gains on divestitures resulted in margin expansion.
See weather related price and volume declines in North America drove margin decline.
Selling general and administrative and R&D costs declined 4% for the full year due to cost synergy realizations and the benefit from disciplined spending actions in total we realized approximately $350 million and cost synergies accelerating $50 million of savings into 2009.
Teen relative to our expectations at the beginning of the year.
Overall these indicators show that we capitalized on the strength of our product pipeline and realized a both market organic growth outside of North America.
We also delivered on our cost synergy commitments and intensified our productivity actions to support sustainable operating EBITDA expansion.
Finally, we acted on our portfolio to divest products that are not aligned with our strategy moving forward.
Turning to slide five we've previously talked about our Lycee as our key performance indicator to assess our effectiveness and using capital to generate earnings.
We are targeting a sustained mid to high teens percent performance on this metric.
Using a fourth quarter average, we delivered a return of 19.8% for 2019.
Well. This result demonstrates our focus on driving effective risk management.
Reducing inventory carryover and maintaining diligence on accounts receivable in collections.
Going forward, our ERP implementation will be critical to maintaining performance at this level.
Harmonized ERP system will allow our teams to have real time transparency and actionable data to drive continued working capital productivity.
Slide six highlights our progress on our five priorities for shareholder value creation. These priorities guide our strategic actions and underscore the quality of the results we are committed to achieve.
So starting first on culture, given the historic market backdrop. It is sometimes easy to forget that we launched a new pure play agriculture company in June with the new courts have a brand new values and a new purpose.
In our first quarter as a public company, we put in place a cultural transformation called execute to win.
This is an example of how we intend to operate differently as core Teva.
2020, we are targeting $30 million in operating EBITDA benefit as we get started on delivering our target of $500 million in incremental operating EBITDA over the next five years.
Moving to capital allocation, we look to invest productively in innovation and growth.
An example is the project announced last quarter to add additional manufacturing capacity for key Sonos and insecticide products.
While continuing to invest in innovation and growth, we are committed to delivering value to shareholders in the form of quarterly dividends and share repurchases.
In total our actions returned approximately $220 million to shareholders in 2019.
On a priority related to developing innovative solutions, we received regulatory approvals in 2019 for several proprietary traits.
In February we received the final important approvals necessary to launch in list eathree certain products and chrome corn products.
In late December China, approve our contested insect control trait in soybeans.
The testa soybean import approval had been in progress in China since 2014.
The receipt of China approval for contested is a necessary step for commercialization of contested eathree product in Latin America.
This is another important milestone toward traits independence.
Today, we announced our attention to accelerate product development and production of enlist ethree soybean products, along with an list one and enlist duo herbicides ahead of the 2021 selling season.
This decision reflects our focus on rapidly ramping up differentiated technology solutions that we expect will enable greater choice and value for growers overtime.
On our priority around best in class cost structure, we delivered $50 million in cost synergies in the quarter and approximately $350 million for the full year.
Overall, we have realized cumulative cost savings through the end of 2019 of $800 million out of the 1.2 billion commitment expected through 2021.
In 2018, we also authorized and launched at ERP Harmonization project that is focused on eliminating approximately $200 million in cost inherited with the spin.
Finally weather related impacts and currency obscured several positive signs of operational momentum in 2019 of note our strong growth and insecticides and our positive organic net sales performance outside of North America.
We took several actions in seed like watching our global retail brand robot and restructuring our brands in North America to create more powerful regional anchor brands that we expect to deliver above market growth in the future and continued momentum on share gains in local markets.
And now I'll turn the call over to Jim to provide some details on our commercial performance.
Jim.
Starting on slide seven I'll provide details on how our teams executed around the globe in terms of topline performance.
The 19 was very complex and dynamic AG market that drove that I'm proud of our teams positioned themselves the win in the market and deliver above market growth.
In North America organic net sales were down 6% due to the weather related delays approximately 11 billion fewer acres of corn and soybeans were planted in the U.S. year over year. As a result seat units were down significantly and reduced applications had a negative impact in crop protection.
All right thing with challenged due to higher replanting, basically beans, and corn, coupled with hiking competitiveness in the marketplace around soybean pricing.
Despite a very challenging environment, our teams achieved share gains in both pioneer corn and soybeans for the year.
Additionally, excluding replant, we're able to hold quite flat in pioneer corn.
In terms of credit protection inventories, we see elevated levels in the U.S. market, primarily in corn and soybean herbicides.
We also saw strong early demand in the fourth quarter pointless chemistry due to 2020 ramp up.
In Latin America, our teams delivered 8% organically led by strong demand for new products.
We successfully implemented the brand positioning for Bob and launch New technology like power for ultra which resulted in share gain in several corn in Brazil.
We did see a more normal start to the second corn crop or suffering in season, which limited volumes in the fourth quarter, but we expect to see those sales in first quarter 2020.
In crop protection, new products like Isoclast insecticide contributed to growth as we obtained registration for the product in Brazil, and the overall insecticide market continues to expand.
In Asia Pacific, we delivered 3% organically or through pricing and volumes under challenging and dynamic market conditions.
Insecticide continue to drive growth, particularly in our spano since product offering given strong local demand.
Got condition limited or opportunity to drive fungicide sales, particularly in South Asia and Australia.
In seed the launch of ever rock brand in the India corn market and in integrated portfolio place around rice continues to be a strategy that enables us to win in the market.
In Europe Middle East Africa gains in volume price led to organic growth of 7% versus the market vacant land 1%.
In Europe strong demand for new products like our like service items or that type of side continue to drive top line growth despite regulatory challenges for other products, including poker costs.
We believe that our seed and crop protection business gained share across Europe . This year, primarily due to strong demand for new products.
In particular, let the market changes in Russia, and Ukraine, and trade market share things in both corn and sunflower seed.
But before I turn the call over to the John I want to quickly make a point on slide eight that I believe sets us apart in the marketplace and as at the center of how we operate each and everyday.
Thats starts with demand creation, our ability to create demand or market pull forward to ever products and services through direct contact the farmers.
At our core is the focus on servicing farmer customers that are believed to be on the ground working closely with them defined technology and agronomic solutions that meet their needs and address their challenges.
We use multiple paths and reach farmers, including strong collaboration with our channel partners and increasing use of digital technology to support face to face contact in the field.
Yes, several illustrations on this chart, including education of customers on solutions to manage and new insect past that was sending their crop and likelihood the introduction of a new rice production system that will deliver economic the title and environmental benefits and the introduction of a new solution that combines seating that protect.
Technologies to address one of the most pressing needs of soybean farmers.
This relentless focus on the customer is something we believe we do better than anyone else in the industry as we engage with more than 10 billion farmers worldwide.
As a result, we gained share in Asia for insecticide, we sold more than 6 million units are providing branded foreign after just launching two years ago, and if overcome portfolio changes in our Brazil corn business as a result in the merger through share gains just to name a few.
I'll now turn it over to they've gone to review segment performance.
Thank you Tim turning to slide nine highlighting the performance for fully in both our crop protection and seats segment.
Crop protection next say its was $6.3 billion down 3% from the prior year.
The decrease was primarily due to keep us in decline from currency.
Organic net sales increased 1% from the prior year, partially due to volume improvement on new and differentiated products. The potent updates from patented and differentiated products, but 2019 was approximately 30% up from approximately 25% in point.
The.
Crop protection operating EBITDA was approximately $1.1 billion.
Down one but that unfavorable currency volume declines in North America, and higher input costs, excluding synergies drove the decline in EBITDA.
Segment delivered on cost synergies and realize a benefit from new products and gain on divestitures.
For the full year crop protection delivered approximately 30 basis points of operating EBITDA margin expansion.
In seat net sales were $7.6 billion down 3% for the year.
Currency was a headwind of group.
Whether related impacts in North America was partially offset by growth in other regions, particularly strong demand and pricing on Bob for ultra upon product in Latin America, new it out to market enhancements in Europe and market share gains in gone in South Asia.
Seed operating EBITDA was approximately $1 billion.
Down 9% versus the prior year.
Reflecting the impact of the not amedica weather related decline market competitiveness in soybeans and unfavorable currency.
Synergies, particularly in R&D and seed production, what a benefit to the segment.
Turning now to slide 10 bought a closer look at several products that contributed to the full segment results and are helping to create a clear thoughtful of future above market growth.
Starting with insecticide with overall market grew 6% 37, net sales split $1.7 billion, an increase of 10% from the private organic net sales were up 14, but thick.
This growth was led by a unique spinoffs and franchise.
Outside of North America, then also contributed 40% of the organic net sales growth for crop protection, despite supply constrain inhibitors region.
As we expect strong market growth in insecticides to continue we recently announced intention to add additional capacity in support of us Denilson insecticide offering.
The combined impact of that investment than most just close will essentially double that of capacity at full utilization to address global market growth in insecticide.
Looking next call net sales flip $5.1 billion, Inrtwenty 90 down 1% from the prior treatment.
With nearly 60% of global currencies originating in North America weather related volume and price impact in that region resulted in the decline.
So it was a challenging year, we had seen green shoots stopping.
Loan corn products, the see China import approval in February two into 90, and but offered commercially across a broad range of job.
In November we shared that is.
We get to drive.
Finally, as Brian Brohm products delivered nearly a seven bushel, but it could average yield advantage.
Measured against all competitors and competitive technology segment.
In 2020 grown product that expected due to present when people think of an online.
With that demonstrated you'd advantage, we expect drilling products delivered low single digit price improvement year over year.
And today, we announced our decision to accelerate production of enlist ethree soybean along with the enlist one and list you will have the SEC.
During the fourth quarter of 2019, we finalize upgrading plan and large scale product development timelines that enable the seat ramp up we believe enlist easily soybean launched in 2019 in the United States and Canada are the most and wants to weed control great technology, but.
Okay.
Following the positive on pump performance of enlist Ethree soybeans in the fall of 2019, very steep supportive feedback from growers retailer.
Independent seat.
So we have accelerated as amp up plans to deliver this important technology, even faster than originally anticipated.
We now estimate that enlist ethree soybean penetration in 2020 will be 20% of total North America acres up from the 10% previously indicated these are just a few examples of tangible actions that underscore our target of growing to put 3%.
So the market all of them.
With that I turn to Paul over to Greg, who will provide details on our financial.
Here is on.
Turning to slide 11 for a brief overview of our fourth quarter performance.
Net sales on a reported basis improved 6% versus the prior year, primarily due to strong volumes in both North America in Latin America.
It's really offset by currency.
Organic sales were up 9% with improvements in both segments.
Seed, we delivered 13% organic growth led by both volume and price improvements, primarily in North America and Latin America.
Specifically, we recorded higher sales in our multi channel brands in the us versus prior year due to improved supply chain performance.
Continued penetration of new products in Latin America drove 8% pricing improvement for the quarter.
In crop protection organic sales improved 7% for the quarter on broad based growth in most regions, which was led by North America with improved volumes from early demand for enlisted herbicides in advance of the 2020 season.
In addition.
Continued ramp of new products, particularly insecticides in Europe Middle East in Africa, and Latin America helped drive volume and price improvements.
Operating EBITDA of $224 million improved by $174 million compared to prior year, largely driven by higher sales in both segments continued realization of cost synergies and gains on divestitures.
Margins benefited from improved mix from Powercore Ultra in Latin America, and demand for new crop protection products like Isoclast insecticide and enlist herbicide.
Gains on divestitures aligned with our ongoing best owner portfolio strategy resulted in approximately $70 million of gains in the quarter.
R&D expense was lower by more than $50 million in the quarter compared to prior year due to cost synergies timing as well as focused actions to control spending.
Turning to slide 12 for a year over year comparison of operating EPS.
Currency was a 19 cents headwind for the year, primarily from the Brazilian real and Europe volume and price amounted to a four cents decline year over year, primarily due to weather related impacts in North America and competitive pricing in soybeans.
Costs were better by eight cents on continued realization of merger related synergies, which were partially offset by higher input costs in seed.
Base tax rate for the year was 19.6% representing a reduction of six cents compared to prior year.
We generated 10 cents a benefit from foreign exchange gains related to our balance sheet hedging program.
Lastly, other was a two cents benefit primarily from gains and divestitures.
Turning now to slide 13, I'll provide our full year guidance for 2020.
Considering our market backdrop, a few key areas that we continue to monitor include commodity price levels near term fluctuations in trade and expected farm level profitability.
There continues to be uncertainties in each of these areas, which impact customer planting decisions and input purchases.
Our full year guidance incorporates caution relative to these uncertainties.
Turning first on net sales, we expect reported net sales to be approximately $14.5 billion up about 4% to 5% over prior year.
This primarily reflects normalized conditions in the north American market, coupled with continued ramp of new products globally in both our crop protection and see segments.
We expect global AG markets will grow at about 2.5% to 3% next year as us corn and soybean area and production are expected to be higher in 2020 on a return to normal planting season weather.
Global demand for agricultural products continues to be strong, helping reduce ending stock in both corn and soybeans market opinions differ on the degree of increase for both corn and soybean area and this will continue to materialize into the first half as growers make their ultimate planting decisions.
[music].
At this point, we expect currency to be relatively flat year over year. However, we're closely monitoring currency movements in Latin America, particularly the retail as well as employing hedging strategies to help managed volatility.
On an operating EBITDA, we expect to deliver about 12% improvement year over year with our expected topline growth and continued focus on delivering cost savings commitments, we expect to improve margins by approximately 100 basis points for the total company.
Turning to operating if yes, we expect to deliver between the dollar and 45 cents and a dollar and 55 cents per share, which would represent a 5% improvement using the midpoint over 2019.
We have provided detailed modeling guidance in the appendix of our presentation.
Now as it relates to key assumptions incorporated into our guidance slide 15 provide more detail.
Starting with above market growth 2020 expectations are led by the recovery to normalize conditions in planted area in the North American market.
We are assuming roughly 11 million acres return with about two thirds going to soybeans.
We will update our assumptions when market data is available as part of the March perspective planting estimates published by the you Sta.
On pricing, we're confident we will realize gains in the low single digits for corn globally.
This is a function of the technology, we offer customers and the value it creates in the market.
In North America, we expect pricing lifting corn due to improved mix, primarily from the large of chrome and proprietary seed treatment offerings.
So we being 2020 will be a continuation of 2018 in terms of price competitiveness.
We expect these trends to potentially amplify this upcoming year and believe soybean prices in North America will be an approximate $50 million headwind on operating EBITDA year over year.
In crop protection, new products will continue to ramp globally as registrations expand in total we expect growth from new product sales in 2020 to be approximately $250 million.
Turning to cost we remain committed and fully expect to deliver on the incremental $200 million in merger related synergies.
In terms of productivity, we expect to capture approximately $30 million in operating EBITDA improvement in 2020, as we execute against project to deliver savings.
As part of this we're considering a restructuring plan that is subject to board approval. This program represents the necessary actions, we need to take as an organization to build on a targeted cost structure that is best in class. We look forward to sharing more details as these plans further develop and we take action.
We expect corporate costs remain on target at less than 1% of sales.
Cost of goods is estimated to have incremental costs of approximately $150 million, which includes higher unit cost and see from lower yields and increased royalty costs, primarily due to the accelerated ramp of enlist ethree soybeans.
To close we expect 2020 to be a euro strong sales and earnings improvement inline with our midterm targets and are confident we have appropriately dialed in risk based on uncertainties as we see them today and are fully committed to deliver on the guidance we are providing.
In addition, the organization is focused on maximizing opportunities as market conditions from and we look to provide updates on those as the year progresses and results materialize.
I'll now turn the call back to Jim.
Thanks, Greg before we go to Q and eight I wanted to offer a few final comments on a remarkable year without a doubt we will remember 2019 as a historic year for our industry and our companies.
As we look forward I'm encouraged by our accomplishments as we navigated unprecedented market conditions to deliver a solid finish to the year.
We've also laid the groundwork to delivered on our commitments going forward.
I've said that core Teva is a different kind of agriculture company and part of that difference is how we support our customers and partner with society.
Agriculture industry has been pacing one of the most challenging periods in history due to weather crude and regulatory burdens, which had limited access to new innovations and safe and reliable seed and crop protection products.
We are encouraged to see a resolution to the trade dispute with China and the passage of the USM CA.
We worked closely with us government to advocate for more transparent and predictable regulatory approvals as part of the trade resolution with China, which helped to secure important approvals for enlistee, three chrome and contested.
Hi testified last July and sort of use Senate Finance committee in support of the USAMRMC away as a vehicle to further expand and modernize North America trade and increased grower and consumer access to innovation.
Both trade deals will be positive over the long term for growers and agricultural demand.
We feel privileged to use our influence as a public company to drive positive societal impacts. It is our purpose, which the lives of those that produce and those who consume.
Ensuring progress for generations to come.
With that I'll turn the call back to Mega.
Thank you Jim let cliff to your question I'd like to remind you that are cautioned on forward looking statements non-GAAP measures and pro forma financial apply to both our prepared remarks and the filing QNX operator, please provide the Q and a instruction.
Thank you the question and answer session will be conducted electronically to ask a question. Please press star one on your telephone keypad. If you only speakerphone. Please make sure. Your mute function is turned off to allow the signal to reach our equipment. We ask that you limit yourself to one question to allow everyone an opportunity to ask a question.
And we'll pause for just a moment to assemble the queue.
And our first question will come from Joel Jackson with BMO capital markets.
Morning, everyone.
Hi, you talk about up in the past about trying to hit our free cash flow conversion target in 2020 of 50% for me on that and 50%.
There wasn't anything on the release of the presentation about data prepared remarks today, maybe give an idea with the puts and takes on free cash flow conversion, where you might be in 2020, where you might be in 2021. Thanks.
Yeah, Great Joel obviously, all of that is still coming together and.
As we as we close are kind of for full year, we're getting new clarity around those numbers, Greg you will hear some more specifics yep. Thanks. Thanks, Tim.
As Tim mentioned 2018 cash flow was that was a complex here with the first half incorporating cash flow elements from our heritage companies and the second half really represented for Tevas results and that validated.
Our ability to manage effectively our seasonal working capital movements.
So we remain committed to our target of converting.
More than 50% of our operating EBITDA into free cash flow, while continuing to grow the topline and improving our margins.
Specifically for 2020, we're focused on driving working capital productivity that will translate into cash flow improvement in the year, where our business is growing and and also you'll notice in our in our guide our capital expenses are lower by roughly 100 million.
In dollars.
And the prior year at the midpoint.
Which is consistent with our commitment to manage capital.
2020, as I mentioned will be the first here that will have standalone cash flows without discontinued operation in spin related uses of cash. So we'll continue to provide.
Updates on our on our progress on free cash flow conversion for 2020 throughout the year.
Thank you. Our next question will come from David Begleiter with Deutsche Bank.
Thank you Jim just on the soybean price headwind I think before you were looking at perhaps soybean price mix to be flat in North America with price town mix up.
Maybe 2% each now I think we're looking at pricing in soybeans to be down maybe 5% or more.
One is that correct into what caused the change are there more severe pricing headwind in North America.
Okay, Great David Thanks for the question.
You're right, we do expect our sleeping pricing, primarily in North America to be down kind of low single digits.
It is a direct response to the market competitiveness, that's going on and and the aggressiveness that is out there in the market.
It is early and.
Early in the in the invoicing process for soybeans, and we're taking a very selective approach.
How we respond to that and Tim you're a lot closer to this on a day to day basis anything else you would you be tightly Jim I would I highlight that we are very.
Very strong performance.
Our in our soybeans product line, especially around a pretty to extend portfolio.
And we did come out with the expectation to being flat.
Your started where our largest competitor in that ran a pretty to extend segment came out of the youre by taking their prices down low single digit so that would kind of the environment. We entered the season in and I think our value proposition and our performance advantage in service is holding up well, but but it's.
Importantly, no that we'd take this $50 million and use it on a very selective basis, they're going to shore up our position. So this is not a broad price adjustment. It really is a very specific competitive response and we can manage this on a customer by customer bases. So just give you some idea that $50 million really represent somewhere will act.
And one half of 1% price adjustment across the across that business. So.
It is very specific very targeted and I think it's really important that we use that to shore up our position in what is a very highly competitive marketplace.
David I would I would just.
As I step back and think we think about overall pricing, we always put that in the context of three areas. The market backdrop as one of them and I think we've dealt with that pretty well globally understanding what our customers are facing.
I always put that into context of our product performance and I think we've got about the best lineup in the marketplace performance perspective, So we're going to continue to price for the value that we deliver and the third element that Tim mentioned is a competitive response out there so.
It really is we're focused on one region and really one product right now and everywhere else in the world.
I'd say across the board I feel really good about about where we are.
Thank you next we'll hear from Vincent Andrews with Morgan Stanley .
Thanks, Good morning, Tim if I just ask you run the on the enlist rollout that you expect.
When do you think you'll have a and listen pioneer germplasm.
And then when you say as you do this can you help us understand sort of.
The skew complexity and maybe a inventory management decisions, you're gonna have to make and this is going to impact working capital at all.
Yeah, Great Vincent Thanks, Thanks for the question.
From from the beginning of the creation of Cortiva, we've talked about creating more choices in the marketplace and so we're very excited about the announcements that we put out today.
About our plans to accelerate the ramp up of in list.
I think about that that ramp up over the next five years would be kind of the timeframe of where we would expect to get to peak penetration.
In it it's about a commitment that we're making.
To the technology and towards that longer term kind of proprietary trading brand strategy that we've been talking to your balance or a real big proof point.
Here today that were on that path. The other thing to remember as we talk about and list. It is a system. It includes branded seed sales. So you're right. There's a there's a pioneer brand element to this but also our other multi brands and maybe I'll.
Average on share a little more about that around how we're going to manage kind of through the inventory cycle that you were I'm asking about remember. This also gives us an out licensing opportunity. So theres income and revenue from from out licensing and it's part of that royalty improvement path.
That we've.
We've talked about.
So with that regimen, we've got a project team up and running we've got a detailed plans over the next three to five years to really manage all of those moving parts you want to share a little more than a detailed.
Okay. Thanks again for the question.
Let's start talking about inventory I think inventory management is a key area of focus for us from a seat productivity standpoint, and we have about a lot of activities initiated as we transition backbone, we stopped daily with no cadieux lymphoma and listening to our.
Jump doesn't so we put a very robust line. So you should not be expected increases in make 30, we continue to work with getting the best pioneer germplasm with the industry in that already launching and listing the fine yet, but I'm I'm with that might be kind of rank them to see it will be what a very robust and make 30 management.
But just in showed that the transition doesn't design and it needs to be than in doing so thank you for the question.
Well go next to Jonas Oxgaard with Bernstein.
Hi, good morning.
Well.
Well I was hoping to talk a bit but the value of comp cast Josh.
At a premium, but hoping marketshare and Ram and and also what happens to Comcast if buyer loses the patent dispute on intact out there fighting right now.
Great. Thanks, Joan this year, if you're you're right. We're very excited to have recently received the China approval that I mentioned, we'll have that opportunity to stack cast with eathree for something for product in the Brazil market that we believe will be differentiated in its again one more step.
Towards that trade independents that we have talked talked about.
We need them still a little bit of time for that product to kind of be ready for the full launch in Brazil, one of the things we're waiting on is.
You approval for the for the stack, we've submitted we anticipate that.
Sometime in 2021, or so we'll get those approvals. We also have to go through the same process that we went through on and lives around the breeding plan accelerate the interpretation of that trade into our background germplasm plasm and that process kind of starts now so.
Earliest come commercialization could be the latter part of 2021.
And it gives us a real opportunity to drive new market share our share in you know in soybeans in Brazil is kind of in the low single digit ranged from here today.
So.
Rather than anything else. You then yes, I think just to add on the question Jonas about up in fact up I've been watching that closely but create some back to a value proposition for the bill that we feel very confident about the value proposition that can get stuff will bring to the marketplace. The Brazilian farmers historically has been always willing to pay for that I pick them.
LNG, which we've been day and chemical Comcast up perspective, we have very confident that we shouldn't be able to exact value for the technology that we have been getting that part of them. So looking public let up and ramp up of context.
Our next question will come from Jeff The caucus with JP Morgan.
Hi, Thanks very much.
On.
Page four in your press release in your.
Crop protection area.
You have.
You have you have good growth in your major sub segments, but in your other category.
I think you go from 155 million revenues to 70 and for the year from 382 to 250 free.
What's behind that decrease and because the decrease is so large has come to an end so that whatever's going on in that category will.
Change for the better in 2020.
As a base case.
Oh, Thanks, Jeff with the question, you're right that that category covers.
A number of other of our other products in the marketplace and as part of our portfolio work can we talk about our best owner mindset.
You see that we began to rationalize pieces of that those portfolios.
And some of those products, which would have been in there with revenue, but very very low margins or contributions to earnings.
Rather than anything else in share about that category. So I think im just building on walk you said I think up on the other category I did not product, sometimes we have talked lucky products et cetera that didn't necessarily pick that there'll be continued to reduce our sales in some of those product to TEP no impact on us. There's also some uh huh.
He needs, which is like a catch all they do have up miscellaneous, but because we had walking through lots systems to see what that that's the idea that category reduces I think the key message of different back to you is that can be continue to expect that rapid ramp up our products as they move forward that is a 30 basis point margin expansion in crop protection.
That does all that inflection of how we're managing that portfolio actively so feel very good about the commitment we have made up to 3% above market growth, which is when could we led by rapid ramp up of lot of new technology that cuts across all the segments. So not on Sunday.
Our next question will come from John Roberts with CBS .
Thank you is Asia, primarily a northern or southern hemisphere market for you I should should know that but I don't I don't know, whether this quarter and it was down meaningfully.
Is representative or is it seasonally low and what's going on in there to cause that decline, especially in the crop protection chemicals.
Yeah Yeah.
John Thanks for the question is primarily is a second half a market for us on a calendar year basis, which we kinda do group, but with the southern hemisphere.
Type performance so.
I don't know Tim you want to share more specifics about what happened this year, yeah I think.
Asia, we've had a.
For years, a very strong growth and we actually have business. It transpires over the course of the year. So it's hard to call. It first or second it really of seasonal business again multiple seasons in different markets. So we actually do play in our Hearts and again you know on a year, we didn't see overall growth in the region.
And growth in both seed and crop protection and continued strength in particular in the insecticide segment. So I think what wouldn't get us as we came through the year and maybe why we took a little bit off the top was.
Talk about the extended impacted the drought in Australia that is significant and we also had a periodic rights over the course of the seasons, especially in the out of the on country, So thinking Tunisia.
Actually add and at one point, we you know we didnt have a type of into the Philippines and all those things.
The impact the seasonal business that we have so it's not quite as I guess is.
Tied to the calendar as as a as we would have in another market. So it does play a little bit northern hemisphere, let a little bit southern hemisphere, but throughout the year. So again I think the the highlight is we grew nicely in both you and crop protection.
You know, 3% overall in crop protection for the year and again double digit growth in our insecticide portfolio, which again is capped by our ability to satisfy those markets. So.
Yeah, we're very satisfied we believe we did outperform the market again, and we continue to have strong expectations for our business in Asia.
A number of our new products that we're launching have rural utility as well as you've heard us talk about begun insecticide.
Expansions that we're making.
Continue to supply has been those products and supply constrained that'll really benefit Asia Pacific as we go forward as well.
Our next question will come from P.J. Juvekar with Citi.
Yes, good morning.
Okay.
Hi can you give me.
Yes.
Yes. Thank you. So again, we have a lot of neighborhoods to pull in 2020, you have new product like at least inquiry that will be on 20% the.
Ecommerce couldn't get stuck cool new products in crop protection.
Good morning.
You know you're addressing new markets.
So when you look at all these levels what are the most important members for you in 2020 that could create protected upside and then what are the big risks for you in 2020.
Thank you.
Great PJ. Thanks, Thanks for the question.
When I.
I think about the other is a key other drivers of additional upsides to the plan that we have laid out I think one of the areas would be pricing, we're basically priced through the first half with offerings. We have out there in the market, though there will be small opportunities here and there to make adjustments, but that second half pricing.
Opportunity is ahead of us and as markets unfolds, we'll certainly have a very very close eye on that I think the second upside area revolves around route to market changes that we've been making you in the U.S. the multichannel and multi brand opportunities that you have there and then in places like Eastern Europe .
Our up we're where we launched the more direct approach and continuing to penetrate in Latin America, that's about driving share and margin going forward.
Then finally I think about the cost category you know, we're clearly laser focused on continuing to drive.
Productivity, we're seeing that show up you see a good evidence of that in the fourth quarter, we're carrying great momentum going into year. So we have a base plan, but with our execute when initiative. We've got 20000 employees now all around the world thinking like owners and bringing up ideas every single day about how to continue to improve productivity.
So this would be another area, where we're going to keep driving.
Well go next to Duffy Fisher with Barclays.
Yes, good morning.
Three questions around and list so Tim talked about your big Roundup ready to extend customer cutting price doesn't list have to match that in the market or can it move to more of a premium.
Second Greg talked about royalty costs, increasing is youre ramping the enlist trade I think that surprises most people because you only unless trade. So I think most people would have thought that was kind of a free onboard. So can you talk about the mechanics of why the Cogs increases is that goes up and then your bump from 10% to 20%.
I've been list this year, how much of that was driven by your own seed and how much of that was driven by third parties.
Okay, Great Duffy. Thanks for the question, you're right, where there's a lot of moving parts within list. We're excited about the announcement and the ability now to talk about it accelerated pace that that we promised you we'd be back to share with you as we closed out the year.
Why don't I, when I turn it to Jim and have you talked about the first during the third when pricing and the improvement from 10% to 20% No hey, good morning, W. The yeah. When I think about it looks like seen today I mean this is a I think it. This is really our first year commercial sales and so yeah, there's a tremendous amount of energy.
And I wouldn't I don't necessarily fee in live.
He three competing head to head with extended the point in time.
Yeah, there's a significant presence in the market from multiple brands are selling the product as well as as for Tevas brands and you know what I would say what Youre seeing is you know some companies are taking a very.
On the approach around penetration pricing, you know really trying to go out there and drive.
Trial and utilization from farmers and and as you can see it had a tremendous.
So.
Again, I don't see it necessarily going head to head with the extent technology in the market per se more about farmers excited to have a choice.
You option in the marketplace and you're seeing those market dynamics, where penetration pricing is it is a is really helping to create some strong momentum for adoption and when you think about the the is the move from 10% to 20% I think you're going I think it's a combination of both.
We were getting I'm very strong uptake on on Eathree, particularly in our multichannel.
Business and obviously the than any other companies who were in the marketplace today are seeing that saying a level of adoption. So I think its broad and really reflects.
Positive energy from you know for farmers from a from a retail channel and others. The companies for having that a that new choice that you option available. So it's a it's great to see that that farmer interest really translate into orders at this point.
And then the other part of your question Duffy is yes. There there are some short term financial implications of the decision.
We've made especially in the royalty area, we fully about those into the to the plan that we have the guidance, we have but Greg you want to share more detailed moment.
Let me clarify a little bit that the loyalty that's increasing is on on the extend portfolio. So our 2020 more LT costs.
Our expected to increase as a as you mentioned by by $50 million and this change by the way does not have paid cash impact.
This is related to a change for the rate of which we recognize per unit loyalty expense for roundup ready to extend and this will require that we report for unit loyalty expense associated with the roundup ready to extend at the current rate rather than the average royalty rate over the life.
Of the established contracts since inception.
Theres no impact to cash as I mentioned associated with this with this change also mentioned that there's a non operating accelerated amortization expense associated with the prepaid royalties that we have recorded on our balance sheet.
Right.
Well go next to Don Carson with Susquehanna.
It's a question on the current EBITDA walk versus what you've talked about in the past so.
As I see it you're about a $180 million lower on your EBITDA outlook is is that all due to headwinds I mean, you in the past you talk about perhaps 100 million of headwinds in 2020 now. So I ended up you get about 250, and specifically you used to talk about a $250 million benefit in 2020 from normalize North American market can.
Additions is that still part of your assumption and you also used to have 100 million dollar benefit from new product growth is that now higher given some of these accelerations you're making.
Great. Thanks, Thanks for the question as we built this 2020 plan clearly it's aligned with our midterm guidance that we've been out I was talking about this this plan is absolutely aligned with those returns we put a plan together we've de risked.
We've got a lot of confidence in this plan.
And we've got an opportunity as you heard me go to drive for some upsides going forward.
So I'm I'm confident that we either propylene considered the uncertainties as we've seen today.
And then.
The plan is consistent with somebody items that we have previously.
Before the two broad categories is a number of growth items. The North America recovery is in there the synergies and productivity are in there and the new the new product portfolio driving forward. So all very consistent with what we shared in the past.
We'd anticipated some headwinds that many of these very consistent with what we've also mentioned around selling prices higher Cogs.
Some investments that we're making to drive growth so.
Correct, you want to do because you're a little more detail.
Almost those categories that Doug. Thank you for the question Paul I'll just walk you through the numbers very quickly here. So you mentioned.
North America Mark return.
252 to normalized weather, we are positioned and and ready to realize this effective rebound of the market year over year.
New products, we're anticipating $100 million a margin improvement as we bring new technology to market, we've talked about synergies and productivity.
Prepared and executing on projects to deliver that $230 million that we've talked about he also mentioned headwinds.
That $100 million those do exist in there primarily related to lower yields than than anticipated and increased commodity prices. That's all confirming information that we previously provided so whats new.
A couple of things here, we talked about our global corn price, increasing we've got a we've got a $100 million as global corn price that we dialed in here. This is proof of the value of the innovation that we're delivering to the market and our ability to price for for that value. We did talk about a 50 million dollar.
It's a reduction in soybean price that style that as well. We also mentioned 50 million dollar.
Got it cost for implementing our ERP system, and then royalty element that we just discussed of another $50 million.
Additionally, we had some.
Portfolio.
Actions in the fourth quarter.
As we executed our that's sort of strategy those elements are not incurring so we're not going to see those those come back and then finally as Jim mentioned.
Yes, with an R&D in selling to bring our new products to market.
Thank you and our last question will come from Adam Samuelson with Goldman Sachs.
Okay, you hear me.
Yeah, we now have.
Thank you.
So a lot of grounds. It's been covered here. This morning, I was hoping maybe just to recap. The 100 800 basis points of anticipated margin improvement in 2020 can you can you walk through the the key kind of components of the pluses and minuses, there and kind of where opportunities may exist.
More risks exists in your mind around that anticipated margin permit.
Thank you.
Great. Thanks, Adam.
Clearly a lot of that margin improvement is consistent with the new product launches that we've been driving bringing you bring in new technology. So that that would be one one aspect second do you hear the strength of our corn portfolio globally in the and the pricing that we are really driving in that portfolio and that's having a nice nice lift.
Coupled with the new products Chrome for example that the Tim mentioned earlier and then finally, we continue to drive productivity.
We've got the since the productivity related to the merger the synergies to continue to flow through and finishing those out over the next two years and then the new productivity that we're driving as a result excuse to win.
Work, so that that those are probably the three major drivers.
Okay, I think that's going to conclude actually the key anything to call today, we really appreciate everyone who joined the call.
So much.
That does conclude today's conference. Thank you all for your participation you may now does.
[music].